Ocera Starts Second Part of Trial of OCR-002 for Liver Disease That Impacts Mental Functioning
Ocera Therapeutics has started the second part of a Phase 1/2a clinical trial of OCR-002 (ornithine phenylacetate) tablets as a treatment for a liver…
ammonia scavenger
Ocera’s Therapy Candidate OCR-002 Prevented Cirrhosis Progression in NAFLD Animal Models
The latest preclinical results of Ocera Therapeutics’ ammonia scavenger OCR-002 showed that it can reduce fibrosis progression in animal models of non-alcoholic fatty liver…
